125545 Apr 2026

: Intravenous or subcutaneous, with IV recommended for hemodialysis patients.

#Biosimilars #FDA #Hematology #PharmaNews #HealthcareInnovation Clinical Spotlight: Retacrit (epoetin alfa-epbx) 125545

The number most commonly refers to BLA 125545 , an FDA Biologics License Application for Retacrit (epoetin alfa-epbx) , which is a biosimilar to Epogen and Procrit used to treat anemia. : Intravenous or subcutaneous, with IV recommended for

For full prescribing information and format items, clinicians can reference the FDA Center for Drug Evaluation and Research records. Below are draft social media posts tailored for

Below are draft social media posts tailored for different professional audiences based on this application:

Biologics License Application (BLA) marks a significant milestone in expanding access to anemia treatments. As a biosimilar to US-licensed Epogen, Retacrit (epoetin alfa-epbx) provides a cost-effective alternative for treating anemia caused by chronic kidney disease, chemotherapy, or zidovudine in HIV-infected patients. Key highlights from the FDA review:

Increased competition in the biologics space continues to drive down healthcare costs while maintaining high standards for patient safety.